Back to Search
Start Over
Comparing four immunosuppressive agents for chronic spontaneous urticaria-A network meta-analysis.
- Source :
-
International immunopharmacology [Int Immunopharmacol] 2023 Oct; Vol. 123, pp. 110577. Date of Electronic Publication: 2023 Aug 09. - Publication Year :
- 2023
-
Abstract
- Background: Immunosuppression is an integral part of treating chronic spontaneous urticaria (CSU), but there is no literature to evaluate the efficacy of multiple immunosuppressive agents.<br />Objective: The comparison of the efficacy, safety, and incidence of adverse effects of four immunosuppressive medicines (tripterygium glycosides, methotrexate, cyclosporine A, and azathioprine) in combination with antihistamines in treating CSU provides a clinical reference and evidence-based medicine for treating CSU.<br />Methods: PUBMED, The Cochrane Library, EMBASE, WANFANG, CNKI, CBM, and clinical trial registration platform were searched to collect relevant randomized controlled trials (RCT) and cohort studies of four immunosuppressive medicines combined with antihistamines for treating CSU. The primary outcomes were the efficacy of weekly urticaria activity score 7 (UAS7) and adverse effects.<br />Results: This study pooled data from seven randomized clinical trials with 410 participants. The standardized mean differences for change in UAS7 were 0.10 (95% confidence interval (CI), 0.01 to 0.68) for cyclosporine A plus antihistamine; 0.03 (95% CI, 0.00 to 0.23) for azathioprine plus antihistamine; 0.52 (95% CI, 0.32 to 0.85) for tripterygium glycosides plus antihistamine; and 1.54 (95% CI, 0.64 to 3.67) for methotrexate plus antihistamine. There were no significant differences in side effects between these medicines in the limited number of trials and clinical samples.<br />Conclusion: Our results indicate that cyclosporine A combined with antihistamine resulted in greater improvements regarding the UAS7 in CSU patients and that tripterygium glycosides are also effective in treating CSU.<br />Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.<br /> (Copyright © 2023. Published by Elsevier B.V.)
- Subjects :
- Humans
Immunosuppressive Agents therapeutic use
Cyclosporine therapeutic use
Methotrexate therapeutic use
Azathioprine therapeutic use
Network Meta-Analysis
Chronic Disease
Histamine H1 Antagonists therapeutic use
Histamine Antagonists
Glycosides therapeutic use
Treatment Outcome
Omalizumab therapeutic use
Randomized Controlled Trials as Topic
Chronic Urticaria chemically induced
Chronic Urticaria drug therapy
Urticaria drug therapy
Drug-Related Side Effects and Adverse Reactions drug therapy
Anti-Allergic Agents therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1878-1705
- Volume :
- 123
- Database :
- MEDLINE
- Journal :
- International immunopharmacology
- Publication Type :
- Academic Journal
- Accession number :
- 37567010
- Full Text :
- https://doi.org/10.1016/j.intimp.2023.110577